Brielle Benyon

Recent study findings demonstrate that certain older women with breast cancer may be able to skip chemotherapy after treatment with endocrine therapy.

A phase 2a trial is kicking off to study frontline GB1211 with the immunotherapy agent Tecentriq in patients with advanced or metastatic non-small cell lung cancer.

Watch Dr. Landon C. Brown, from Atrium Health Levine Cancer Institute, discuss approaches to hormone therapy, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Tian Zhang, from UT Southwestern Medical Center, discuss novel agents, during the CURE Educated Patient Prostate Cancer Summit.

Watch Dr. Jeremie Calais, from UCLA, discuss novel imaging strategies, during the CURE Educated Patient Prostate Cancer Summit.

Toby Keith announced in a post on his social media channels that he has been undergoing treatment for stomach cancer since last fall.

From Tampa Bay Buccaneers quarterback Tom Brady letting children with cancer dye his hair orange to the name of a cancer drug causing controversy at the Scripps National Spelling Bee, here’s what’s happening in the cancer space this week.

Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone.

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.

From chef Gordon Ramsay sharing a meal with a 13-year-old fan with Ewing sarcoma, to a dermatologist on a playground spotting a mother’s skin cancer, here’s a look at what’s happening in the cancer space this week.

The Food and Drug Administration granted a fast track designation to PDS0101 plus Keytruda for the treatment of patients with recurrent or metastatic HPV16-related head and neck cancer.

If approved, Omblastys will be the first FDA-approved drug for children with neuroblastoma that has spread to the central nervous system or leptomeninges.

The FDA approval of Fylnetra, a biosimilar for Neulasta, has the potential to offer patients with cancer a neutropenia treatment option at a lower cost.

Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.

Both Opdivo plus Yervoy and Opdivo plus chemotherapy were approved by the Food and Drug Administration to treat patients with esophageal squamous cell carcinoma.

A clinical trial just launched to study Vaxinia — a novel cancer vaccine — in patients with previously treated advanced solid tumors.

For patients with advanced epithelial ovarian cancer, there were little — if any — differences in survival outcomes depending on when they received surgery.

Patients can still talk to their clinicians about enrolling in a sub-study of the FIRELIGHT-1 trial, analyzing tovorafenib plus pimasertib in progressive or refractory solid tumors with MAPK pathway aberrations.

Actor and cancer advocate Patrick Dempsey predicts that more focus will be put on complementary cancer care, such as nutrition and environmental factors, over the next several years.

Myelofibrosis may cause major impairments to a patient’s quality of life, which is why it is pertinent that patients work with their clinicians to address these side effects.

The FDA approved Vidaza for the treatment of pediatric patients with juvenile myelomonocytic leukemia.

Watch Dr. Srdan Vestovsek, from The University of Texas MD Anderson Cancer Center, discuss novel agents and clinical trials in myelofibrosis, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile Shammo, from Rush University Medical Center, discuss differentiating an essential thrombocythemia diagnosis, during the CURE Educated Patient MPN Summit.

NX-5948 may be able to pass through the blood-brain barrier in patients with B-cell malignancies, potentially making it a promising option for patients with disease in their central nervous system.

From PGA Tour golfer Justin Thomas’ new sun-protection line to soap opera actress Marnie Schulenburg’s breast cancer death and the first child to receive CAR-T cell therapy celebrating 10 years cancer-free, here’s what’s happening in the cancer space this week.

Despite Latino and Hispanic men being more likely to present with higher-risk prostate cancer, they are less likely to receive treatment for their disease compared to other ethnicities.

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

Dying does not have the be scary, and there are resources available to help patients and their loved ones, explained an expert.